

HAPVIDA PARTICIPAÇÕES E INVESTIMENTOS S.A.

CNPJ N.º 05.197.443/0001-38 NIRE 233.000.392-71


NOTICE TO THE MARKET


HAPVIDA PARTICIPAÇÕES E INVESTIMENTOS S.A. (B3:HAPV3) (Hapvida or Company), in compliance with current regulations and in continuation to the notices to the market about the impacts of Covid-19 on the Company, comes to update its shareholders and the market in general on the measures we continue to implement.

Since the beginning of the pandemic, the Company has been committed to assuring its beneficiaries all the safety and care necessary for the challenges related to access to healthcare during this period of the pandemic. Measures included: (i) new care units were opened and existing ones were expanded; (ii) the largest and most modern telemedicine service platform was developed, the only one with facial recognition; and (iii) there was an increase in the number of beds and health professionals to overcome the entire demand during the two waves of the Covid-19 pandemic.


Emergency care, hospitalization and death figures

We have been observing a consistent reduction in the main indicators that we monitor in the cities where we operate. On July 23, last Friday, the Company performed 3,133 emergency care services, 35 hospitalizations and 9 deaths occurred. Below is the evolution of the main consolidated numbers in our own network:






In **Manaus (AM)**, North region, the first city to be affected by the second wave of the pandemic, it is possible to observe that all indicators returned to their baseline levels for more than 4 months:




In **Fortaleza (CE)**, Northeast region, the case curves of both patients treated in emergencies and patients admitted to hospitals with suspected Covid-19 have already shown a strong decrease, as well as the number of deaths:





In the **countryside of the state of São Paulo**, Southeast of Brazil, a region that was hit later by the second wave of the pandemic and which showed some resistance in the decrease of cases, there is already a consistent reduction in hospitalizations and deaths:





Demobilization of areas dedicated to Covid-19

As disclosed in the Notice to the Market dated June 28, 2021, the Company had 963 beds (522 infirmary beds and 441 ICU beds) for Covid-19 treatment. Currently, the Company has 104 beds (34 infirmary beds and 70 ICU beds) dedicated to Covid-19 cases, a 90% reduction when compared to the last update, reflecting the consistent decrease in the number of hospitalizations of infected patients and the rate of hospital discharges. In regions that present descending curves or are close to their baseline levels, we remain with additional equipment and medications capacity for an eventual increase in hospitalizations.

Vaccination

The vaccination program against Covid-19 in Brazil continues to advance, with the country reaching satisfactory levels of vaccination. We are confident that with the advance of vaccination, the number of hospitalizations and deaths by Covid-19 will remain at a reduced level.

All of our medical and hospital management experience has helped us to manage and minimize the impacts of Covid-19 on our operations and to continue taking care of our customers and employees with the usual care. We remain vigilant, monitoring the impacts of the pandemic on our business and acting proactively to ensure service to our customers and contribute to society.

Fortaleza, Ceará, July 26, 2021

MAURICIO TEIXEIRA

Chief Financial and Investor Relations Officer